Mutations found in the pncA gene of mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China

Journal of International Medical Research

Volumn 37, Issue 5, 2009, Pages 1430-1435

  Zhang, H ^a,b   Bi, L J ^a   Li, C Y ^c   Sun, Z G ^c   Deng, J Y ^b   Zhang, X E ^b  

^a INSTITUTE OF BIOPHYSICS   (China)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

^c Department of Cellular and Molecular Biology   (China)

Author keywords

Mycobacterium tuberculosis; pncA; Pyrazinamidase; Pyrazinamide

Indexed keywords

AMIDASE; BACTERIAL DNA; PNCA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CHINA; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; TUBERCULOSIS;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; CHINA; DNA, BACTERIAL; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; PYRAZINAMIDE; TUBERCULOSIS;

EID: 77649207225     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323000903700517     Document Type: Article

References (29)

1. World Health Organization (WHO): Global Tuberculosis Control. WHO Report 2009. Geneva: WHO, 2009 (available at: http://www.who.int/GlobalAtlas/predefinedReports/TB/PDF_Files/chn.pdf).
2. Johnson R, Streicher E, Louw G, et al: Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006; 8: 97-111.
3. Mitchison DA: The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
4. Heifets L, Lindholm-Levy P: Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 1992; 145: 1223-1225.
5. Scorpio A, Zhang Y: Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2: 662-667.
6. Canetti G, Fox W, Khomenko A, et al: Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull WHO 1969; 41: 21-43.
7. Morlock GP, Crawford JT, Butler WR, et al: Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 2291-2295.
8. Wayne LG: Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis 1974; 109: 147-151.
9. Scorpio A, Lindholm-Levy P, Heifets L, et al: Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-543.
10. Cheng SJ, Thibert L, Sanchez T, et al: pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec Canada. Antimicrob Agents Chemother 2000; 44: 528-532.
11. Suzuki Y, Suzuki A, Tamaru A, et al: Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR based in vitro system. J Clin Microbiol 2002; 2: 501-507.
12. Hou L, Osei-Hyiaman D, Zhang Z, et al: Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol Infect 2000; 124: 227-232.
13. Bishop KS, Blumberg L, Trollip AP, et al: Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int J Tuberc Lung Dis 2001; 5: 952-957.
14. McCammon MT, Gillette JS, Thomas DP, et al: Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States- Mexico border region. Antimicrob Agents Chemother 2005; 49: 2210-2217.
15. Lee KW, Lee JM, Jung KS: Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci 2001; 16: 537-543.
16. Rodrigues V de F, Telles MA, Ribeiro MO, et al: Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. Antimicrob Agents Chemother 2005; 49: 444-446.
17. Miyagi C, Yamane N, Yogesh B, et al: Genetic and phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis complex isolates in Japan. Diagn Microbiol Infect Dis 2004; 48: 111-116.
18. Barco P, Cardoso RF, Hirata RD, et al: pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother 2006; 58: 930-935.
19. Lemaitre N, Sougakoff W, Truffot-Pernot C, et al: Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase pncA. Antimicrob Agents Chemother 1999; 43: 1761-1763.
20. Marttila HJ, Marjamaki M, Vyshnevskaya E, et al: pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother 1999; 43: 1764-1766.
21. Sreevatsan S, Pan X, Zhang Y, et al: Mutations associated with pyrazinamidase resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997; 41: 636-640.
22. Wade MM, Volokhov D, Peredelchuk M, et al: Accurate mapping of mutations of pyrazinamide- resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn Microbiol Infect Dis 2004; 49: 89-97.
23. Portugal I, Barreiro L, Moniz-Pereira J, et al: pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob Agents Chemother 2004; 48: 2736-2738.
24. Mestdagh M, Fonteyne PA, Realini L, et al: Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 2317-2319.
25. Brown TJ, Tansel O, French GL: Simultaneous identification and typing of multi-drugresistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB. J Med Microbiol 2000; 49: 651-656.
26. Huang TS, Lee SS, Tu HZ, et al: Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chemother 2003; 47: 3672-3673.
27. Park SK, Lee JY, Chang CL, et al: pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect Dis 2001; 1: 4.
28. Hannan MM, Desmond EP, Morlock GP, et al: Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J Clin Microbiol 2001; 39: 647-650.
29. Zhang H, Deng JY, Bi LJ, et al: Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase. FEBS J 2008; 275: 753-762.